Improved Neuronal Cell Survival in 3D Model of Alzheimer's
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Invex Therapeutics Ltd. has released findings on the effects of Exenatide in a three-dimensional model of Alzheimer's Disease, indicating improved neuronal cell survival. The study showed that low and moderate doses of Exenatide significantly increased cell viability under conditions mimicking oxidative stress and ferroptosis, common pathways in Alzheimer's progression.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Invex Therapeutics Ltd. on 6ix
Earlier from Invex Therapeutics
- Quarterly Activities Report and Appendix 4C
- Invex receives R&D Tax Rebate
- ATO Class Ruling Return of Capital
- Appendix 4D and Half year report
- Invex and Peptron Mutually Terminate Manufacturing Agreement
Later from Invex Therapeutics
- Invex Receives $0.22m R&D Tax Rebate from UK Government
- Appendix 4E and Annual Report to shareholders
- Trading Halt
- Suspension from Quotation
- Corporate Update
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics